Invention Grant
![1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors](/docs/US/2024-04-23/US11964990B2/abs.jpg.600x600.jpg)
- Patent Title: 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
-
Application No.: US18156987Application Date: 2023-01-19
-
Publication No.: US11964990B2Publication Date: 2024-04-23
- Inventor: George A. Doherty , Vikram Bhat , Andrew S. Judd , Andrew J. Souers
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Agent Glen Gesicki
- Main IPC: C07D519/00
- IPC: C07D519/00
![1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors](/abs-image/US/2024/04/23/US11964990B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides for compounds of Formula (I)
wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
Public/Granted literature
- US20230234971A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors Public/Granted day:2023-07-27
Information query
